High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Determine the effects of escalated dose of daunorubicin in induction treatment of adult
patients with acute myelogenous leukemia who are younger than 60 years of age.